Clinical Trials

119 enrolled

Breast Neoplasms

NCT03070886 2026-01-14

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

612 enrolled

Stage I Prostate Adenocarcinoma AJCC v7

NCT03258320 2026-01-12

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients

300 enrolled

Prostatic Neoplasms

NCT06028737 2025-05-06

OCTASUR

150 enrolled

Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms

NCT01779206 2025-04-08

ADAPT

4,936 enrolled

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

136 enrolled

HER2-positive Breast Cancer

NCT02923258 2024-06-20

Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer

224 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05627752 2024-02-28

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

120 enrolled

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

503 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03600831 2024-01-09

Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma

434 enrolled

Esophageal Squamous Cell Carcinoma

NCT03607656 2023-12-18

CHANGE

270 enrolled

Stomach Neoplasms

NCT05125055 2023-11-22

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

80 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03879122 2022-10-26

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

135 enrolled

Prostatic Neoplasms

NCT02661971 2022-07-11

RAMSES/FLOT7

180 enrolled

Stomach Neoplasms

NCT05253066 2022-02-23

Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

130 enrolled

Breast Neoplasms

NCT05189067 2022-01-12

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

190 enrolled

HER2-positive Breast Cancer

NCT04576143 2021-08-12

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

260 enrolled

HER2-negative Breast Cancer

NCT04393584 2021-04-13

RusGCG-01

538 enrolled

Phase 2/3 Active not recruiting

Gastrointestinal Neoplasms, Stomach Neoplasms

NCT02568839 2020-08-13

PREDIX HER2

202 enrolled

Breast Neoplasms

NCT04138992 2020-06-30

A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer

150 enrolled

Disease Free Survival

NCT01907529 2019-08-09

TENDENCY

300 enrolled

Breast Neoplasms

NCT01216644 2019-06-19

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

716 enrolled

Pathologic Complete Response, Stomach Neoplasms

NCT02959749 2018-02-14

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

147 enrolled

Progression Free Survival

NCT02326285 2018-01-23

NeoIntercal

Phase 2/3 Terminated

1 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03373708 2017-12-18

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

200 enrolled

Breast Diseases, Breast Neoplasms

NCT03349177 2017-11-21

Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy

200 enrolled

Breast Neoplasms

NCT02780778 2016-05-23

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02409199 2015-11-18

A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer

66 enrolled

Stomach Neoplasms

NCT01829178 2015-05-13

Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma

30 enrolled

Gastrointestinal Neoplasms

NCT01065870 2014-01-29

Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)

64 enrolled

Pancreatic Neoplasms

NCT01999933 2013-12-03

Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer

600 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT01523015 2013-02-05

Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction

100 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT00525642 2007-09-06

Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer

603 enrolled